Femasys expands OB/GYN reach via Minnesota Women’s Care adoption
Minnesota Women's Care adopts FemVue and FemaSeed across four locations to streamline fertility diagnostics and treatment.
Latest Femasys News & Updates
See the latest news and media coverage for Femasys. We track all announcements, press releases, and industry mentions in real time, all in one place.
Women's reproductive health technology company
femasys.com- Headquarters
- Suwanee, United States
- Company type
- Public company
- Number of employees
- 10–60
- Industry
- Biotechnology & Medical Research
Last updated
Latest news about Femasys
In short: Femasys expanded fertility care via new OB/GYN partnerships, advanced FemBloc's FDA pathway, and completed a $30M financing.
Company announcements
Femasys partners with UNC Health to deploy its fertility portfolio
The collaboration introduces FemVue diagnostics and FemaSeed treatments into local OB/GYN offices, enabling earlier fertility care before specialist referrals.
Femasys announces FDA approval of modular PMA pathway for FemBloc
The company advances its non-surgical birth control technology toward US market entry while building commercial infrastructure.
Femasys secures a thirty million dollar private financing round
Nantahala Capital leads the deal, which provides immediate capital and future proceeds tied to specific corporate and market milestones.
Media coverage
Femasys Inc. (FEMY) faces compliance risks on Nasdaq, stock hits 52-week low
Economic Observer Network: Femasys Inc. (FEMY) completed financing in August and currently faces risks of triggering Nasdaq compliance requirements. Compliance risk situation: Financing round completed in August, and previously underwent reverse stock split; market information shows that after the reverse stock split, the stock price continued to fall cumulatively, hitting a 52-week low, with daily trading volume reaching extremely low levels at times. Continuous net outflow + micro-cap market value means there is a risk that further equity issuance or financing could trigger Nasdaq's minimum bid price/market capitalization compliance requirements, which may occur irregularly as an event. The above content is compiled based on public information and does not constitute investment advice...
Scott Chudnoff, MD, highlights the benefits of Fembloc for permanent contraception | Contemporary OB/GYN
Femasys secures FDA approval to advance final FemBloc trial phase and $12 million financing, with potential to reach $58 million. News release. Femasys Inc. November...
Femasys partners with UNC Health for fertility services By Investing.com
The partnership will make FemVue and SpermVue fertility diagnostics available to patients, along with FemaSeed Complete, an in-office intratubal insemination solution positioned as a first-line...
FDA clears FemVue Controlled for in-office tubal assessment | Contemporary OB/GYN
Femasys has continuously worked to provide fertility and nonsurgical permanent birth control options for patients, including the novel transcervical birth control option FemBloc, which was...
Never miss news about Femasys
Track Femasys and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Femasys competitors & trending companies
Browse news for competitors to Femasys and other trending companies.
Instagram